Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Fredrik Wetterlundh as Head of Human Resources. Fredrik will join Sobi on 9 April 2018 and be part of Sobi’s Extended Leadership Team.
Fredrik Wetterlundh joins Sobi from Pfizer, where he held the position of Global Human Resources Lead in Pfizer’s Global Supply organisation. He has extensive international experience in leading business-driven HR organisations, processes and projects in Asia, Europe, and North and Central America, and has supported a number of successful mergers and acquisitions and divestitures. Fredrik holds a degree in HR Management from the University of Lund, Sweden.
Guido Oelkers, CEO and President of Sobi, sees the appointment as a valuable addition to the company. “His experience from the pharmaceutical industry, numerous company integrations and the global roles he has held will be of great value for Sobi, supporting our organisation and our journey to become a global leader in rare diseases,” he said.
Fredrik says he is excited to be joining Sobi. “Sobi is a value-driven company with highly experienced employees and a strong culture. These are valuable assets to build on. I look forward to contributing to Sobi’s growth strategy with my experience in implementing effective organisation and people strategies,” he said.
Source: Sobi™
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.
